Absence of PTEN/MMAC1 pseudogene in mice.

The PTEN gene encodes a phosphatase that acts as a tumor-suppressor gene and is mutated in a variety of human cancers. Alterations of the PTEN gene in these tumor samples were identified using exon-by-exon analysis of the gene using single-stranded conformational polymorphism or direct sequencing of PTEN cDNA. However, in humans, mutational analysis of a PTEN cDNA template can produce false results because of a highly conserved PTEN processed pseudogene that shares more than 98% homology with the coding region of functional PTEN. PTEN-knockout mice develop tumors, suggesting that mouse tumor models are useful in vivo model systems to study PTEN function. Any mutational analysis of mouse PTEN cDNA may also produce false results if mice contain a highly conserved PTEN pseudogene. In this paper, we demonstrate the absence of any PTEN pseudogene in the mouse and discuss the significance of this observation for the mutational studies of the PTEN gene in mouse tumor models.

[1]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Bolen,et al.  Transcriptional analysis of the PTEN/MMAC1 pseudogene, ΨPTEN , 1999, Oncogene.

[3]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[4]  M. Kattan,et al.  Elevated expression of caveolin is associated with prostate and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  C. Sawyers,et al.  Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. , 1998, Journal of the National Cancer Institute.

[6]  M. FitzGerald,et al.  A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 , 1998, Oncogene.

[7]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[9]  A. Sakurada,et al.  PTEN1 is frequently mutated in primary endometrial carcinomas , 1997, Nature Genetics.

[10]  J. Boyd,et al.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. , 1997, Cancer research.

[11]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[12]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[13]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[14]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[15]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[16]  L. Donehower,et al.  Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. , 1995, Oncogene.

[17]  A. Weiner,et al.  Nonviral retroposons: genes, pseudogenes, and transposable elements generated by the reverse flow of genetic information. , 1986, Annual review of biochemistry.

[18]  E. Vanin,et al.  Processed pseudogenes: characteristics and evolution. , 1984, Annual review of genetics.